Stream 5 Session #1: Free communications - Diabetes complications- insights from clinical trials, cohort studies and national audits
Tracks
Meeting Room 103
| Wednesday, August 19, 2026 |
| 8:30 AM - 10:30 AM |
| Meeting Room 103 (Level 1) |
Speaker
Prof Jerry Greenfield
Divisional and Laboratory Head
Victor Chang Cardiac Research Institute
Chairperson
Biography
Prof So Hun Kim
Division of Endocrinology and Metabolism Department of Internal Medicine
Inha University College of Medicine
Chairperson
Biography
Prof Yan Bi
China
Nanjing Drum Tower Hospital / Affiliated Hospital of Medical School / Nanjing University
Liraglutide and empagliflozin versus linagliptin on reversion of mild cognitive impairment in Type 2 diabetes (LIGHT-MCI): A multicenter, randomized clinical trial
8:30 AM - 8:45 AMBiography
Professor Yan Bi is vice president of Nanjing Drum Tower Hospital and head of endocrinology. She is a distinguished talent of China’s National High-Level Talent Program, a lead expert for the National Science and Technology Major Project on chronic diseases, and a standing committee member of the Chinese Diabetes Society.
Fei Yan Shi
Master's Student
West China Hospital / Sichuan University
Association of diabetic foot ulcer with increased non-calcified plaque volume and high-risk coronary features in Type 2 Diabetes mellitus
8:45 AM - 9:00 AMBiography
Shi Feiyan is a postgraduate student working under the supervision of Professor Ran Xingwu. Her research focuses on diabetic foot ulcers and their systemic cardiovascular complications, utilizing advanced imaging techniques to explore atherosclerosis in type 2 diabetes.
Assoc Prof Samantha Hocking
Endocrinologist
Royal Prince Alfred Hospital
Efficacy and safety of oral semaglutide 25 mg in adults with overweight/obesity: the OASIS 4 RCT
9:00 AM - 9:15 AMBiography
Samantha Hocking is an Endocrinologist at the Royal Prince Alfred Hospital and a Clinical Academic at the University of Sydney. Her main research interest is precision medicine exploring how personalised medicine can both predict, prevent and improve the management of metabolic disease, particularly diabetes.
Dr Tannia Cyriac
Research Officer
University of Wollongong
Impact of a combined lower carbohydrate and Mediterranean diet on Metabolic Syndrome severity: A randomised controlled trial
9:15 AM - 9:30 AMBiography
Dr. Tannia Cyriac is a Research officer in the Exercise and Cardiovascular Research group at the University of Wollongong focused on lifestyle intervention clinical trials. With a background in Medicine and public health her research interests include cardiometabolic disease prevention and management, immunometabolism and adiposity.
Dr Joel Lasschuit
ADFR Manager
National Association of Diabetes Centres
ADFR – an evolving national quality-improvement platform highlighting opportunities in care of diabetes foot disease
9:30 AM - 9:45 AMBiography
Dr Joel Lasschuit (BMedSc, MBBS(Hons), FRACP, PhD) is an endocrinologist and researcher dedicated to improving outcomes for people with diabetes-related foot complications. He is a Staff Specialist in Endocrinology and Clinical Lead of High Risk Foot Services at St Vincent’s Hospital Sydney, and Manager of the Australian Diabetes Foot Registry.
Shuchun Chen
Director
Hebei General Hospital
The association between glucose metabolism status and hepatic steatosis/fibrosis: Results from NHANES 2017–2020
9:45 AM - 10:00 AMBiography
Zhao Hang, Attending Physician in the Department of Endocrinology at Hebei General Hospital. He holds a Ph.D. and has been dedicated to diabetes-related research since graduation.
Zhanjun Guo
China
Xiangya Hospital Central South University
Association between glycemic variability and cognitive function in patients with Type 2 Diabetes Mellitus: A study based on continuous glucose monitoring and metabolomics
10:00 AM - 10:15 AMBiography
Dr. Zhanjun Guo is currently studying at Xiangya Hospital of Central South University. His research focus is on cognitive dysfunction related to diabetes, obesity and its metabolic complications.
Mrs Emily-Jane Sharpington-Recny
Medical Advisor
Medical Advisor
Mechanistic kidney effects of semaglutide by baseline SGLT2i use in type 2 diabetes: A post-hoc analysis of the REMODEL trial
10:15 AM - 10:30 AMBiography
Katherine R. Tuttle, MD, FASN, is Executive Director for Research at Providence Inland Northwest Health and Professor of Medicine at the University of Washington. She is an internationally recognised leader in diabetic kidney disease and served as a senior investigator on the REMODEL trial
